Jonathan Allan, GENERAL COUNSEL & Corporate Secretary at Stoke Therapeutics, Inc. (STOK), sold 17,584 shares at $31.76 ($550K) on 2025-12-05, disclosed to the SEC on 2025-12-05.
Scheduled sale ($550k) by GENERAL COUNSEL & Corporate Secretary under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $30.76 | 824 | $25K | 4.6% |
| 2 | $31.32 | 194 | $6K | 1.1% |
| 3 | $31.08 | 5,437 | $169K | 30.7% |
| 4 | $31.08 | 5,437 | $169K | 30.7% |
| 5 | $31.33 | 1,004 | $31K | 5.7% |
| 6 | $31.76 | 2,344 |
| $74K |
| 13.5% |
| 7 | $31.76 | 2,344 | $74K | 13.5% |
| Total | $31.26 avg | 17,584 | $550K | 100% |
| Filing → |
| STOK | SELL | 2026-06-18 | $44K | — | Filing → |
| STOK | SELL | 2026-03-24 | $626K | — | Filing → |
| STOK | SELL | 2026-03-19 | $569K | — | Filing → |